Next results · Q4 2026Projected
Feb 25, before the open
Thu, Feb 25, 2027in 99 days
Projected from its last 8 releases. The company has not named the day yet.
- Quarter
- Q4 2026 · Ends about Dec 31, 2026
- 10-K window
- Feb 19 – Mar 1
Read against Q4 2025
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
- Revenue
- $434.93M
- Revenue, change from a year earlier: Q3 2026 +2.3%, Q2 2026 +0.8%, Q1 2026 +2.4%, Q4 2025 −1.7%
- Net income
- -$1.70M
- Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
- EPS
- —
- EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Results day
Typical moveA typical move of 15.0% either way
Up after 4 of 12, down after 8.
The stock’s move from the last close before each release to the first close after it, over the last 12 releases. Largest: +25.2% after Q3 2024.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
When it reports
- Usual day
- Varies
- Session
- before the open
- After quarter end
- 29 to 56 days
- 10-Q filed
- 29 to 35 days
- over its last 8
- 10-K filed
- 53 to 57 days
- over its last 8
Based on 8 prior 10-K filings.
Integra Lifesciences Holdings Corp · CIK 917520 · Engraved from SEC EDGAR